2 citations
,
March 2025 in “Journal of Translational Autoimmunity” This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.
86 citations
,
August 2011 in “Toxicological sciences” In this study, researchers found that TCDD exposure accelerated differentiation and altered gene expression in human epidermal cells, indicating the epidermal barrier as a target of TCDD-activated AHR.
40 citations
,
September 2019 in “Molecular and Cellular Endocrinology” This paper discusses mechanisms by which various chemicals disrupt male sexual differentiation, concluding that mixture risk assessments should include a broader set of compounds beyond phthalates to address cumulative reproductive health risks.
May 2023 in “Journal of Endocrinology and Reproduction” This study found that in primary cicatricial alopecia, reducing cholesterol production and targeting EMT modulators like PPARγ, AhR, AGTR, and TGFβ with siRNA may help mitigate hair follicle damage by modulating epithelial-mesenchymal transition, suggesting potential therapeutic strategies for slowing PCA progression.